Slide 1: KOL Discussion of STRO-002 Phase 1 Interim Dose Expansion Data
NON-CONFIDENTIAL 2022 KOL Discussion of STRO-002 Phase 1 Interim Dose Expansion Data January 5, 2022 5:00pm ET / 2:00pm PT Sutro Biopharma “NASDAQ: STRO Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Agenda for Today
Agenda for Today Topic Speakers Opening Comments Welcome & Agenda Review Forward-Looking Statements Ed Albini, Chief Financial Officer CEO Opening Comments Study Objectives and Overview Bill Newell, Chief Executive Officer Data Presentation Study Objectives and Overview STRO-002 Phase 1 Dose Expansi
Slide 4: Agenda for Today: Welcome Dr. R. Wendel Naumann
Agenda for Today Welcome Dr. R. Wendel Naumann Phase 1 STRO-002-GM1 Co-Principal Investigator Dr. Naumann is currently the Director of Minimally Invasive Surgery in Gynecologic Oncology and Professor in the Department of Ob/Gyn at the Levine Cancer Institute, Atrium Health. Dr. Naumann did his resid
Slide 5: Patient Characteristics in Dose Expansion Cohort
5 Dose Expansion STRO 002 Patient Characteristics in Dose Expansion Cohort Interim data for dose expansion are as of November 8, 2021 Patients Randomized & Dosed Safety Evaluable (as of Nov 8, 2021) N=43 RECIST v1.1 Evaluable One Post-Baseline Scan N=33 Not Yet Evaluable No Post Baseline Scan N=8 Di
Slide 6: Maximum Change in Tumor Target Lesions: Dose Response Demonstrated
6 20% -30% 2 pts had 0% Δ Maximum Change in Tumor Target Lesions (N=33) Partial Response 4.3 mg/kg 5.2 mg/kg Treatment ongoing as of Nov 8, 2021 PR confirmed by next scheduled scan (after Nov. 8, 2021) Dose Expansion STRO 002 Dose Response Demonstrated Interim data suggest that 5.2 mg/kg starting do
Slide 7: Objective Response by RECIST v1.1
Starting Dose Best Overall Response (BOR) 4.3 mg/kg 5.2 mg/kg All Comers Evaluable patients N=16 N=17 N=33 PR 3 4 7 PR confirmed by next scheduled scan post Nov. 8, 2021 0 4 4 Total PR 3 8 11 ORR (%) 18.8% 47.1% 33.3% SD 10 4 14 PD 3 5 8 7 Dose Expansion STRO 002 Objective Response by RECIST v1.1 33
Slide 8: Robust Anti-tumor Activity and Disease Control Demonstrated
Dose Expansion STRO 002 Robust Anti-tumor Activity and Disease Control Demonstrated Responders experienced rapid tumor reduction or a steady deepening of response Change from baseline (%) Weeks since first treatment 20 -30 -100 0 Change in Sum of Diameters for Target Lesions Over Time (N=33) Startin
Slide 9: Encouraging Response Rates and Preliminary Data on Durability
Encouraging Response Rates and Preliminary Data on Durability Interim data suggests initiating with 5.2 mg/kg followed by a dose adjustment Treatment Duration on Patients with at Least One Dose (N=43) Dose Expansion STRO 002 Median Duration of Response has not been reached and 23 patients remain on
Slide 10: Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level
Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level Ongoing Partial Response with 72% reduction in tumor burden Dose Expansion STRO 002 Initial diagnosis: Stage IV ovarian cancer, Jan 2020 3 Prior Regimens: Resistant to 1st Neoadjuvant / adjuvant Carbo / Taxol / Taxotere Refrac
Slide 11: TPS > 25% suggests ~70% of patients may benefit from STRO-002
11 TPS > 25% suggests ~70% of the patient population may benefit from STRO-002 ORR by TPS Expression Levels (Total Samples N=33) Dose Expansion STRO 002 TPS Overall TPS ≤ 25% TPS > 25% TPS > 50% TPS > 75% ORR 33.3% 12.5% 40.0% 42.1% 43.8% Number of patient samples N=33 N=8 N=25 N=19 N=16 PR(1) 11 1
Slide 12: Emerging Safety Profile is Manageable and Consistent with Prior Studies
Emerging Safety Profile is Manageable and Consistent with Prior Studies No new safety signals were observed, including the absence of keratopathy 4.3 mg/Kg (N=23) 5.2 mg/Kg (N=20) Total (N=43) Grade 3 n (%) Grade 4 n (%) Grade 5 n (%) Grade 3 n (%) Grade 4 n (%) Grade 5 n (%) Grade 3 n (%) Grade 4 n
Slide 13: Dose Expansion Data Provide Initial Insights on Go-Forward Strategy
13 Dose Expansion STRO 002 Dose Expansion Data Provide Initial Insights on Go-Forward Strategy Emerging data show dose response and a path for potential enrichment strategy Total of 11 confirmed PR (1) out of 33 RECIST v1.1 evaluable patients 33% ORR, across all FolRα expression levels and both dose
Slide 14: Expanding the STRO-002 Franchise
Dose-escalation cohort 39 patients, enrollment completed August 2020 Dose-expansion cohort 44 patients enrolled in US and Spain sites, enrollment completed November 2021 Combo study with bevacizumab Trial is open and enrolling patients FPI planned for early 2022 Registration-directed trial Pending F
Slide 15: Q&A Session
NON-CONFIDENTIAL 2022 KOL Discussion of STRO-002 Phase 1 Interim Dose Expansion Data Q&A Session January 5, 2022 5:00pm ET / 2:00pm PT